NASDAQ:JAGX Jaguar Health (JAGX) Stock Price, News & Analysis $4.67 -0.09 (-1.89%) Closing price 03:59 PM EasternExtended Trading$4.64 -0.03 (-0.64%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Jaguar Health Stock (NASDAQ:JAGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Jaguar Health alerts:Sign Up Key Stats Today's Range$4.40▼$4.7050-Day Range$4.76▼$25.7552-Week Range$4.41▼$540.00Volume41,989 shsAverage Volume27,894 shsMarket Capitalization$3.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Read More… Remove Ads Jaguar Health Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreJAGX MarketRank™: Jaguar Health scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Jaguar Health. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Jaguar Health are expected to decrease in the coming year, from ($0.80) to ($2.06) per share.Price to Book Value per Share RatioJaguar Health has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Jaguar Health's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.30% of the float of Jaguar Health has been sold short.Short Interest Ratio / Days to CoverJaguar Health has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Jaguar Health has recently decreased by 96.25%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJaguar Health does not currently pay a dividend.Dividend GrowthJaguar Health does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.30% of the float of Jaguar Health has been sold short.Short Interest Ratio / Days to CoverJaguar Health has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Jaguar Health has recently decreased by 96.25%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.46 News SentimentJaguar Health has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Jaguar Health this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Jaguar Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Jaguar Health insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.38% of the stock of Jaguar Health is held by insiders.Percentage Held by InstitutionsOnly 12.04% of the stock of Jaguar Health is held by institutions.Read more about Jaguar Health's insider trading history. Receive JAGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter. Email Address JAGX Stock News HeadlinesJaguar Health outlines key Q2 2025 catalysts for crofelemer programsApril 1 at 12:44 PM | msn.comJaguar Health, Inc. (NASDAQ:JAGX) Q4 2024 Earnings Call TranscriptApril 1 at 12:44 PM | msn.comPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.April 2, 2025 | Brownstone Research (Ad)Jaguar Health reports FY24 EPS ($5.23) vs. ($1.79) last yearApril 1 at 2:43 AM | markets.businessinsider.comJaguar Health, Inc. (JAGX) Q4 2024 Earnings Call TranscriptMarch 31 at 10:07 AM | seekingalpha.comJaguar Health announces results of veterinary oncologists on Canalevia-CA1March 29, 2025 | markets.businessinsider.comJaguar Health’s Napo granted FDA Type C Meeting to discuss OnTarget studyMarch 27, 2025 | markets.businessinsider.comJaguar Health, Inc.: Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget StudyMarch 27, 2025 | finanznachrichten.deSee More Headlines JAGX Stock Analysis - Frequently Asked Questions How have JAGX shares performed this year? Jaguar Health's stock was trading at $25.25 at the beginning of the year. Since then, JAGX shares have decreased by 81.5% and is now trading at $4.68. View the best growth stocks for 2025 here. How were Jaguar Health's earnings last quarter? Jaguar Health, Inc. (NASDAQ:JAGX) announced its earnings results on Tuesday, August, 13th. The biotechnology company reported ($101.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($30.00) by $71.00. The biotechnology company earned $2.72 million during the quarter. Jaguar Health had a negative trailing twelve-month return on equity of 326.62% and a negative net margin of 360.13%. When did Jaguar Health's stock split? Jaguar Health's stock reverse split on the morning of Thursday, May 23rd 2024. The 1-60 reverse split was announced on Thursday, May 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did Jaguar Health IPO? Jaguar Health (JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers. How do I buy shares of Jaguar Health? Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Jaguar Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jaguar Health investors own include CrowdStrike (CRWD), NVIDIA (NVDA), Meta Platforms (META), Digital Turbine (APPS) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/13/2024Today4/02/2025Next Earnings (Estimated)4/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JAGX CIK1585608 Webwww.jaguaranimalhealth.com Phone(415) 371-8300FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,300,000.00 Net Margins-360.13% Pretax Margin-365.71% Return on Equity-326.62% Return on Assets-67.02% Debt Debt-to-Equity Ratio1.65 Current Ratio1.84 Quick Ratio1.36 Sales & Book Value Annual Sales$10.48 million Price / Sales0.29 Cash FlowN/A Price / Cash FlowN/A Book Value$4.02 per share Price / Book1.15Miscellaneous Outstanding Shares656,000Free Float11,797,000Market Cap$3.02 million OptionableNo Data Beta0.80 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:JAGX) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jaguar Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jaguar Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.